Community Schedule

Enter at least 4 characters

3 results showing for: 'influenza'

  1. Vaccinations
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine    Medsafe Data Sheets   New Zealand Formulary.   Hospital Medicines List.   PDF Schedule - Refer from page 303.
- Only on a prescription
- No patient co-payment payable
  • Inj 30IU diphtheria with 40IU tetanus and 25mcg pertussis toxoids, 25mcg pertussis filamentous haemagglutinin, 8mcg pertactin, 80D-AgU polio virus, 10mcg hepatitis B antigen, 10mcg H. influenzae type b with tetanus toxoid 20-40mcg in 0.5ml syringe
    • Brand Fully subsidised brand. Infanrix-hexa
    • Pharmacode2459396
    • Subsidy $0.00
    • Measure / Qty per 10
    Infanrix-hexa to be Principal Supply on 1 December 2024

  1. Funded for children meeting any of the following criteria

    1. Up to four doses for children under the age of 10 years for primary immunisation; or

    2. An additional four doses (as appropriate) for (re-)immunisation of children under the age of 18 years post haematopoietic stem cell transplantation; or

    3. An additional four doses (as appropriate) for (re-)immunisation of children under the age of 10 years who are post chemotherapy; pre or post splenectomy; undergoing renal dialysis and other severely immunosuppressive regimens; or

    4. Up to five doses for children under the age of 10 years receiving solid organ transplantation.

  2. Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.

  3. Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

  1. Vaccinations
Haemophilus influenzae type B vaccine    Medsafe Data Sheets   New Zealand Formulary.   Hospital Medicines List.   PDF Schedule - Refer from page 304.
- Only on a prescription
- No patient co-payment payable
  • Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml
    • Brand Fully subsidised brand. Hiberix
    • Pharmacode2087758
    • Subsidy $0.00
    • Measure / Qty per 1
    (Hiberix Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml to be delisted 01 December 2024)
  • Inj 10 mcg vial with diluent syringe
    • Brand Fully subsidised brand. Act-HIB
    • Pharmacode2404699
    • Subsidy $0.00
    • Measure / Qty per 1
    Act-HIB to be Principal Supply on 1 December 2024

  1. One dose for people meeting any of the following:

    1. For primary vaccination in children; or

    2. An additional dose (as appropriate) is funded for (re-)immunisation for people post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or

    3. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

  2. Contractors will be entitled to claim payment from the Funder for the supply of Haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.

  3. Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

  1. Vaccinations
Influenza vaccine    Medsafe Data Sheets   New Zealand Formulary.   Hospital Medicines List.   PDF Schedule - Refer from page 307.
  • Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) - Maximum of 1 inj per prescription - Only on a prescription - No patient co-payment payable
    • Brand Fully subsidised brand. Influvac Tetra (2024 formulation)
    • Pharmacode2670143
    • Subsidy $120.00
    • Measure / Qty per 10

    1. INFLUENZA VACCINE

      is available each year for patients who meet the following criteria, as set by Pharmac:

      1. all people 65 years of age and over; or

      2. people under 65 years of age who:

        1. have any of the following cardiovascular diseases:

          1. ischaemic heart disease, or

          2. congestive heart failure, or

          3. rheumatic heart disease, or

          4. congenital heart disease, or

          5. cerebo-vascular disease; or

        2. have either of the following chronic respiratory diseases:

          1. asthma, if on a regular preventative therapy, or

          2. other chronic respiratory disease with impaired lung function; or

        3. have diabetes; or

        4. have chronic renal disease; or

        5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

        6. have any of the following other conditions:

          1. autoimmune disease, or

          2. immune suppression or immune deficiency, or

          3. HIV, or

          4. transplant recipients, or

          5. neuromuscular and CNS diseases/disorders, or

          6. haemoglobinopathies, or

          7. are children on long term aspirin, or

          8. have a cochlear implant, or

          9. errors of metabolism at risk of major metabolic decompensation, or

          10. pre and post splenectomy, or

          11. Down syndrome, or

        7. are pregnant; or

      3. children 4 years of age and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or

      4. people under 65 years of age who:

        1. have any of the following serious mental health conditions:

          1. schizophrenia, or

          2. major depressive disorder, or

          3. bipolar disorder, or

          4. schizoaffective disorder, or

        2. are currently accessing secondary or tertiary mental health and addiction services; or

      Unless meeting the criteria set out above, the following conditions are excluded from funding:

      1. asthma not requiring regular preventative therapy,

      2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

    2. Contractors will be entitled to claim payment for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

    3. Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

  • Rectangle page icon symoblising a PDF. PDF
  • A tick icon. Fully subsidised
  • An oval with the number 29 in it. Unapproved medicine under Section 29
  • An asterisk symbol. 3 or 6 months should be dispensed at once
  • Two duplicate pages icon. Click to copy
  • A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
  • OP Original pack
  • Sole Subsidised Supply



Email enquiry@pharmac.govt.nz to provide feedback: compliments, suggestions and complaints.